GH-deficient Dwarf Mice Research Articles

Insulin-like growth factor-binding protein-3 protease activity in Snell normal and Pit-1 deficient dwarf mice.

Partial proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) lowers its affinity for IGFs. Presumably, this leads to destabilization of the ternary IGF-IGFBP-3-acid-labile subunit complex in the circulation and an increased bioavailability of IGFs. We investigated the effect of GH on IGFBP-3 proteolysis by comparing serum from normal mice and GH-deficient dwarf mice. While normal mouse serum degraded 125I-IGFBP-3, this activity declined with age. In contrast, serum from dwarf mice displayed strong proteolytic activity at all ages tested (up to 10 weeks). In dwarf mice of 4 weeks and older, this activity could not be inhibited by EDTA and 1,10-phenanthroline, indicating the presence of a divalent cation-independent protease. Prolonged treatment with GH (4 weeks) did not decrease the overall potency of the serum to degrade IGFBP-3, but partially restored the ability of EDTA to inhibit IGFBP-3 protease activity. GH deficiency therefore appears to induce a new kind of IGFBP-3 protease. Similarly, serum from hypophysectomized rats displayed enhanced IGFBP-3 protease activity compared with control rat serum. These results suggest that a protease induced under conditions of severe GH deficiency may contribute to making IGFs optimally available to the tissues.

Hypophysiotropic somatostatin expression during postnatal development in growth hormone-deficient Ames dwarf mice: mRNA in situ hybridization.

Lifelong deficiency of growth hormone (GH) in spontaneous or transgenic dwarf mice has been shown to be accompanied by reduced hypophysiotropic somatostatin (somatotropin release-inhibiting hormone, SRIH) expression in hypothalamic anterior periventricular nucleus (PeN). However, the postnatal developmental pattern of SRIH expression in the absence of GH is unknown. Therefore, SRIH mRNA levels in GH-deficient Ames dwarf (df/df) mice and normal (DF/?) littermates were determined both in adults, to compare with other GH-deficient models, and at selected days of postnatal development, to determine the effects of GH deficiency on SRIH neuron development. DF/? and df/df mice of both sexes at postnatal ages 1, 3, 7, 14, 21 and 60 days (adult) were examined. In situ hybridization and image analysis were used to quantify the relative abundance of total SRIH mRNA in the PeN, and SRIH mRNA per cell was determined in PeN and medial basal hypothalamus (MBH). In adult df/df mice, total PeN SRIH mRNA was 45% (p < 0.05) of that in DF/? littermates, which is consistent with studies of other GH-deficient dwarf mice. In developing animals, SRIH expression in the PeN of DF/? mice began at 3 days of age and increased at subsequent ages to reach adult levels. In df/df mice, PeN SRIH mRNA levels at 60 days were significantly greater than at 1-21 days of age (p < 0.05). However, levels were not different over 1-21 days of age, and were consistently lower in df/df than DF/? mice. The difference in total PeN SRIH mRNA between df/df and DF/? mice was statistically significant at 7 days, and at each subsequent age. There were no differences between DF/? and df/df mice in the number of grains per cell in either PeN or MBH at any age. Thus, the reduced total hypophysiotropic SRIH mRNA in GH-deficient Ames dwarf mice appears developmentally shortly after initial detectability of SRIH in the PeN. Because SRIH mRNA per cell was the same for DF/? and df/df mice, the decreased total mRNA in dwarfs suggested reduced SRIH cell numbers in PeN, which was corroborated by immunocytochemical findings. The reduction of SRIH in df/df mice at 7 days of age suggests that GH production during embryonic or very early postnatal development is important to activation of PeN SRIH transcription.

Influence of Hypothalamus and Ovary on Pituitary Function in Transgenic Mice Expressing the Bovine Growth Hormone Gene and in Growth Hormone-Deficient Ames Dwarf Mice1

Female transgenic mice expressing the bovine (b) growth hormone (GH) gene exhibit reduced fertility, and GH-deficient dwarf mice are sterile. However, in these animals, the influence of the hypothalamus and ovary on pituitary functions is poorly understood. To address this issue, female Ames dwarf mice received twice-daily injections of either vehicle or bGH (25 micrograms/injection per mouse) for 12 days. Vehicle-injected normal female siblings served as controls. On Day 7, these mice and adult female transgenic mice expressing the bGH gene with mouse metallothionein-I promoter, as well as their normal littermates, were ovariectomized. Two experiments were conducted with each group of mice: on Day 8 after ovariectomy of transgenic mice and their normal siblings, and on Day 4 after ovariectomy of dwarf mice and their normal siblings. In experiment I, mice were primed with 0.5 micrograms estradiol benzoate (EB) in oil and 24 h later received injections of 5 micrograms EB/100 g BW. The next day, these mice received injections of either saline or GnRH (1 ng/g BW), and 15 min later blood was obtained via heart puncture under anesthesia. In experiment II, ovariectomized mice either received injections of oil or were primed with 0.5 micrograms EB and 24 h later treated with 10 micrograms EB/100 g BW in oil. On the next day, blood was obtained as in experiment I. In transgenic mice and in their normal littermates, plasma bGH, FSH, LH, and prolactin levels were measured. In dwarf mice and in their normal siblings, plasma LH and insulin-like growth factor (IGF)-I levels were determined. Bovine GH was secreted in transgenic mice, but this hormone was not detectable in normal siblings. Expression of the GH gene resulted in attenuated (p < 0.001) FSH response to GnRH treatment, while LH response was similar to that in controls. The ovariectomy-induced increases in plasma FSH (p < 0.001) and LH (p < 0.05) levels were decreased in transgenic mice. The absolute circulating FSH levels were also decreased (p < 0.001) in estrogen-treated transgenic mice, while plasma LH level were similar in normal mice and in mice bearing the bGH gene. The ovariectomized transgenic mice were hyperprolactinemic. In ovariectomized dwarf mice, IGF-I was not detectable, and GH treatment induced its secretion. In these mice, plasma LH concentrations were reduced (p < 0.05), and GH treatment increased (p < 0.01) LH secretion. In oil-injected ovariectomized dwarf mice, the plasma LH response to GnRH treatment was reduced (p < 0.001), and GH administration normalized this response. The negative feedback effect of estrogen on LH secretion was decreased (p < 0.025) in dwarf mice. These indicate that the alterations in gonadotropin secretion are dependent on the duration of exposure of neuroendocrine system to bGH and that bGH alters the effects of GnRH and estrogen on gonadotropin secretion in these two widely divergent experimental mouse models.

Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits.

The thymus gland is a central lymphoid organ in which bone marrow-derived T cell precursors undergo maturation, eventually leading to the migration of positively selected thymocytes to the T-dependent areas of peripheral lymphoid organs. This process occurs under the influence of the thymic microenvironment, by means of secretory polypeptides and cell-cell contacts. The thymic microenvironment is a tridimensional cellular network composed of epithelial cells (its major component), macrophages, dendritic cells, fibroblasts and extracellular matrix elements. The epithelial reticulum is a heterogeneous tissue, in which a particular lymphoepithelial structure has been isolated in vitro: the thymic nurse cell complex, which possibly creates particular microenvironmental conditions for thymocyte differentiation. Additionally, thymic nurse cells are useful tools to study mechanisms involved in intrathymic T cell migration, including neuroendocrine influences. Previous data showed that thymic hormonal function can be modulated by hormones and neuropeptides, including growth hormone. Interestingly, GH acts pleiotropically on the thymic epithelium increasing cell growth and expression of extracellular matrix ligands and receptors, the latter resulting in an enhancement of thymocyte adhesion to the epithelial cells and thymocyte release from thymic nurse cells. The role of GH on thymus development is further stressed by the findings obtained with GH-deficient dwarf mice. Besides the precocious decline in serum thymulin found in these animals, a progressive thymic hypoplasia occurs, with decreased numbers of CD4+CD8+thymocytes, both defects being largely restored by long-term GH treatment. The effects of GH in the thymus are apparently mediated by IGF-1. Enhancement of thymulin secretion induced by GH, as well as the stimulation of thymocyte adhesion to thymic epithelial cells can be prevented in vitro by treatment with antibodies for IGF-I or IGF-I receptor. Moreover, in both systems IGF-I alone can yield similar effects. Also, the enhanced concanavalin-A mitogenic response and IL-6 production by thymocytes observed in GH-treated mice can be detected in animals treated with IGF-I. Lastly, mouse substrains selected for high or low IGF-I circulating levels exhibited differential thymus developmental patterns correlating with IGF-I levels. A further conceptual aspect concerning the GH-IGF-I-mediated control of thymus physiology is the recent demonstration of an intrathymic production of these molecules, leading to the hypothesis that, in addition to the classical endocrine pathway, GH-IGF-I-mediated paracrine and autocrine pathways may also be implicated in the control of thymus physiology. In any case, such control is exerted pleiotropically, with modulation in the expression of several genes in different cell types of the organ. In this respect, it is exciting to imagine a role of GH-IGF-I loops in shaping the intrathymically generated T cell repertoire.